Director Mattaj comments on the Nobel Prize for Chemistry 2020
07 October 2020
Director Mattaj comments on the Nobel Prize for Chemistry 2020
Director Iain Mattaj commented the winners of the 2020 Nobel Prize for Chemistry: “The Nobel prize awarded to Charpentier and Doudna is very well deserved. CRISPR is a typical example of a discovery which initially seemed interesting to a limited, niche group of scientists studying bacterial evolution. It has since become a fundamental tool for biology and subsequently an experimental tool for therapies linked to human health.
Genetic engineering, first achieved in 1972, is the ability to manipulate the structure and composition of DNA molecules by “cutting and pasting”. It allows us to learn what genes do, how they work and why they go wrong.
CRISPR technology has the potential to make the “dream” of genetic engineering come true: to make specific, targeted changes in the genome of any organism.
Since the breakthrough of Charpentier and Doudna, thousands of experiments have been published showing that CRISPR systems work to enable “cut and paste” experiments in the genomes of a large variety of organisms, including human cells and organoids in culture. Off-target side effects are limited and can be measured and controlled. This progress is already enabling clinical trials of the use of CRISPR in certain types of cancer treatment. Once its safety is established, the method will be applicable to many genetic disease states, and also potentially to treat parasites that infect or damage humans, like viruses.
Meanwhile, researchers are applying the method to a wide variety of questions. At Human Technopole for example, we are using it to help understand neurodevelopmental disorders, to identify promising drug targets in different cancers and to understand aspects of the evolution of the brain.”
An international collaborative study led by Human Technopole, Candiolo Cancer Institute IRCCS in Turin, the University of Turin, and the Wellcome Sanger Institute in Cambridge (UK) has identified new factors associated with therapeutic response in colorectal cancer. The research has led to the development of a machine-learning model capable of accurately predicting the effects of cetuximab, a drug in clinical use, on different colorectal tumour subtypes. Funded by the AIRC Foundation, the study paves the way to identifying molecular features that could serve as biomarkers for predicting treatment response in patients with this type of cancer.
The Human Technopole Director, Marino Zerial, has been awarded the 2024 Mercurio Prize in the “Research and Development” category, in recognition of the excellence of his research in the field of cell biology. Zerial, renowned for his studies on the mechanisms of endocytosis and cellular transport, has made significant contributions to the understanding of cellular dynamics, with potential therapeutic applications for diseases such as liver conditions.
Researchers from Human Technopole, the Institute of Molecular Biotechnology and Bicocca University established a method for developing brain assembloids that allows reproducing salient aspects of the antero-posterior polarity of the human cerebral cortex in vitro and opens new possibilities for disease modelling. The study is published in Nature Methods.
Meet Clelia Peano, Head of the National Facility for Genomics. The Facility offers cutting-edge services to develop robust experimental and analytical workflows to explore different genomic research areas, including DNA and RNA analysis, chromatin structure, and epigenetic mechanisms regulating transcription. The goal is to enhance genomic research in all its aspects, benefiting the entire Italian scientific community.
Manage Cookie Consent
This website uses technical cookies to provide you with a better browsing experience and, subject to your consent, profiling cookies to offer you information and advertising in line with your preferences. For more details, you can consult our cookie policy by clicking on the link below, or set your preferences by clicking "set preferences". By selecting "accept cookies" you consent to the use of all types of cookies while you can revoke your consent by clicking on "refuse". By deciding to refuse or closing the banner, only the technical cookies necessary for the correct functioning of the site will be activated.
Technical cookies (required)
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Third party cookies for statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Third party cookies for profiling
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.